El Menshawy Nadia, El-Ghonemy Mohamed Sabry, El-Ashwah Shaimaa, Elkerdawy Heidi, Abbas Ramy, Abdelhakiem Mostafa, Saif Maha, El-Sebaie Ahmed
Hematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Clinical hematology unit, oncology center, Faculty of Medicine, Mansoura university, Egypt.
Afr Health Sci. 2024 Sep;24(3):216-229. doi: 10.4314/ahs.v24i3.26.
Resistance to tyrosine kinase inhibitors (TKIs) is an obstacle facing CML patients in spite of the high cure rate. In this context, a study association between IGFBP (1, 2, 3) genes expression and their proteins in CML with the response to TKI has been implicated.
115 newly diagnosed CML in chronic phase (CP) followed up over 12 months under TKI. 116 apparently healthy individuals were used as a control. RT-qPCR amplification was used for detecting IGFBPs genes expression, and ELISA technique was used for measuring serum IGFBPs.
IGFBP-1 and IGFBP-3 genes expression, as well as their serum levels, were significantly higher in CML patients, whereas IGFBP-2 gene expression was not. Interestingly, IGFBP-1 gene expression and IGFBP-1 serum levels were significantly higher in resistant patients compared to responder patients. However, the expression of IGFBP-2, 3 genes and their serum were insignificant.
IGFBP-1 gene expression and its serum were significantly correlated with resistance. It is currently recommended that IGF-receptor inhibitors be developed and utilized. We are hoping to optimize the cure rate for CML treated with TKIs.
尽管酪氨酸激酶抑制剂（TKIs）对慢性粒细胞白血病（CML）患者的治愈率较高，但耐药性仍是他们面临的一个障碍。在这种情况下，一项关于IGFBP（1、2、3）基因表达及其蛋白与CML患者对TKI反应之间的关联研究被提了出来。
115例新诊断的慢性期（CP）CML患者在TKI治疗下随访12个月。116名明显健康的个体作为对照。采用RT-qPCR扩增检测IGFBPs基因表达，采用ELISA技术检测血清IGFBPs。
CML患者中IGFBP-1和IGFBP-3基因表达及其血清水平显著升高，而IGFBP-2基因表达则不然。有趣的是，与反应者患者相比，耐药患者中IGFBP-1基因表达和IGFBP-1血清水平显著更高。然而，IGFBP-2、3基因的表达及其血清水平无显著差异。
IGFBP-1基因表达及其血清水平与耐药性显著相关。目前建议开发和使用IGF受体抑制剂。我们希望优化TKI治疗CML 的治愈率。
